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ABSTRACT 
Tapentadol Hydrochloride is a centrally acting opioid analgesic used for the treatment of musculoskeletal pain. The aim of the present study is 
to release the drug at a controlled rate by formulating solid lipid nanoparticles using Hot Homogenization method. In the present study SLN’s 
are prepared by using Glycerol Monostearate and Stearic acid as lipids and Poloxamer-188 as stabilizer in different ratios in order to get the 
optimized formulation. The solid lipids and drug were evaluated for drug interactions by using FTIR, DSC, and surface morphology by SEM in 
order to select the effective formulation. The prepared formulations (F1-F12) were evaluated for Particle size, Zeta potential, %Entrapment 
efficiency, in vitro drug release studies and stability studies. The FTIR spectra revealed that there is no significant interaction between the drug 
and lipids. SEM images revealed that the particles are spherical in shape with smooth surface. The particle size was found as 101.9 nm, Zeta 
potential was found as -18.1mV, % Entrapment Efficiency (%EE) was found as 88.7±0.36 and the % drug release was found as 97.8±0.60 in 10 
hours following first order release kinetics and Higuchi model. The Tapentadol Hcl loaded SLN’s of F3 formulation shows more effective when 
compared to all the other formulations. All the results shows that the Tapentadol Hcl SLN’s can be effectively used for treat ing severe pain by 
controlling the rate of release at the targeted site.  
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INTRODUCTION  
Nanoparticles are the colloidal carriers ranges in the size of 
10-1000 nm prepared by using natural/ synthetic polymers 
in order to target the drug at the specific site and to release 
the drug at controlled rate. To overcome the toxicity and the 
high cost of the polymer solid lipids has been put forward to 
prepare solid lipid nanoparticles [1]. 
Solid lipid nanoparticles (SLN’s) were introduced in 1991 
which represent an alternate carrier system to the 
traditional colloidal carriers such as emulsions, liposomes, 
polymeric microspheres and polymeric nanoparticles. 
Nanoparticles made from solid lipids are attracting major 
attention as novel colloidal drug carrier for intravenous 
applications as they have been proposed as an alternative 
particulate carrier system [2]. This system consists of 
spherical solid lipid particles which ranges in the size of 
nanometer, dispersed in aqueous surfactant solution. 
Generally, the solid lipids are made of hydrophobic core 
having a single layer of phospholipids coating. These solid 
lipid nanoparticles have potential of carrying both lipophilic 
drugs and hydrophilic drugs as they are amphipathic in 
nature [3].  
Neuropathic pain (NP) has been defined as “pain caused by a 
lesion or disease of the somatosensory nervous system. NP 
is a common condition that results from various aetiologies 
and can be categorised into either peripheral or central NP 
syndromes. Central NP is the result of a central lesion or 
disease such as stroke, multiple sclerosis or spinal cord 
injury, whereas peripheral NP occurs from dysfunction or 
damage to peripheral nerves. [4]. Tapentadol Hydrochloride 
is a centrally acting opioid analgesic used for the treatment 
of neuropathic pain. It belongs to the class of benzenoids 
with dual mechanism of action as an agonist of the μ-opioid 
recptor and as a norepinephrine reuptake inhibitor. It’s 
bioavailability is about 32% with an elimination half-life of 
about 4 hours [5]. In the present study solid lipid 
nanoparticles are prepared and loaded with tapentadol 
hydrochloride in order to release the drug at the targeted 
site at a controlled rate.  
MATERIALS AND METHODS 
Materials 
Glycerol Monostearate and Stearic Acid was obtained from 
Qualikems fine chem. Pvt. Ltd., Vadodara, Gujarat, India and 
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NR chem.., Mumbai, India. Poloxamer-188 was obtained 
from Merck life sciences Pvt. Ltd., Mumbai, India. Tapentadol 
Hydrochloride was obtained as a gift sample from Halmark 
Pharmaceuticals Pvt. Ltd., India. 
Method 
Preparation of Tapentadol Hydrochloride Solid Lipid 
Nanoparticles by Hot Homogenization method 
Weighed quantities of Tapentadol hydrochloride and 
Polaxamer-188 were dissolved in hot distilled water at  
temperature of 70˚c .GMS was melted at temperature of 70˚c 
and added drop wise to the hot aqueous solution under 
stirring at 500 rpm for 30 mins by using a mechanical 
stirrer. This results in the formation of emulsion which was 
homogenised by using a homogenizer at 1000 rpm for 
45mins. This results in the formation of Solid lipid 
nanoparticles which were stored in a refrigerator [6]. 
Evaluation of Tapentadol Hydrochloride Solid Lipid 
Nanoparticles 
Fourier transform infrared spectroscopy (FTIR) 
The samples of Tapentadol Hydrochloride and optimized 
formulation (F3) was triturated and mixed well with IR 
grade potassium bromide in 1:100 ratio. The mixture was 
introduced in the sample holder of FT-IR instrument and 
scanned in the range from 4000 to 400 cm-1 to obtain the 
spectrum. The obtained spectrum was compared with the 
spectrum obtained for Tapentadol Hcl and physical mixture 
of Tapentadol Hcl with a Glyceol monostearate and Stearic 
acid [7]. 
 
Table-1:  FTIR Spectrum Interpretation 
Functional Group Freq. (cm-1) range of 
Functional group 
Freq. (cm-1) range of Pure 
drug 
Freq. (cm-1) range of 
optimized formulation 
Amine /Amide N-H 3400- 3100 `3414.12 3423.76 
Alkene C=C 1580-1500 1546.96 1519.96 
Alkane-C-H 1350-1480 1352.14 1383.01 
-OH 1000-1200 1170.83 1163.11 
 
Table-2: Composition of formulations from F1 to F12 
Chemicals F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Drug (%) 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
Glycerol 
monostearate(%) 
1.2 1.2 0.6 0.6 0.85 0.85 - - - - - - 
Stearic acid(%) - - - - - - 1.2 1.2 0.6 0.6 0.85 0.85 
Poloxamer-188(%) 0.25 0.8 0.25 0.8 0.25 0.8 0.25 0.8 0.25 0.8 0.25 0.8 
Distilled water(ml) 100 100 100 100 100 100 100 100 100 100 100 100 
 
Differential Scanning Colorimetry (DSC) 
The samples of drug and optimized formulation (F3) were 
kept in desiccator for 24 h before thermal analysis. The 
accurately weighed sample, 5 mg was hermetically sealed in 
aluminum crucible and heated at a constant rate of 
10℃/min over a temperature range of 25 to 200 ℃. An inert 
atmosphere was maintained by purging nitrogen gas at a 
flow rate of 20 mL/min. An empty aluminum pan was used 
as a reference [8]. 
Scanning Electron Microscopy (SEM) 
The surface morphology of lyophilized Tapentadol 
Hydrochloride SLN’s was visualized using SEM (Zeiss SEM 
EVO-18, Carl Zeiss Microscopy). The water suspended 
nanoparticles were mounted on a glass slide as a thin smear 
and left to dry. The particles on dried glass slide were 
subjected to gold sputtering and the slide was attached on 
SEM holder using a double side carbon tape mounted on an 
aluminum stud. The SEM photomicrographs were captured 
by operating at an accelerating voltage of 20 kV electron 
beam at desired magnification [9]. 
Zeta Potential 
The zeta potential parameter is used to characterize the 
charge on the surface of the nanoparticles that plays a vital 
role in determining the stability of the formed nanoparticles. 
Zetasizer Nano ZS 90 (Malvern Instruments, UK), which 
calculates the zeta potential by determining the 
electrophoretic mobility and then applying the henry 
equation was used to determine zeta potential of the 
formulations (F1-F12). The electrophoretic mobility is 
obtained by performing an electrophoresis experiment on 
the sample and measuring the velocity of particles using 
laser doppler velocimetry [10]. 
Percentage Entrapment Efficiency (%EE) 
The method for determination of entrapment efficiency was 
based on the amount of Tapentadol Hcl recovered from 
supernatants. It was assumed that the rest of the Tapentadol 
Hcl used during preparation had been encapsulated. The 
blank used was the supernatant obtained after 
centrifugation of dummy nanoparticles (without drug) at 
10,000 rpm for 30 minutes at 15℃. The supernatant 
obtained was diluted and analysed Spectrophotometrically 
at 272 nm.  Following equation was used to calculate 
entrapment efficiency [11]. 
%EE=Wt. of drug used in formulation-Wt of unbound 
drug in supernatant/Wt. of drug used in formulation x 
100 
In-vitro drug release studies 
Franz diffusion cell was employed for in-vitro 
characterization of transdermal formulations. This is a 
reliable method for the prediction of drug transport across 
skin from topical formulations. The receptor compartment 
of the diffusion cell was filled with 20 mL of phosphate 
buffered saline pH 7.4 and invitro drug release studies were 
carried out using synthetic cellophane membrane. The 
prepared solid lipid nanoparticles were placed in the donor 
compartment. The assembly was constantly maintained at 
32.0 ± 0.5 °C at 100 rpm. Samples (1.0 mL aliquots) were 
then withdrawn at suitable time intervals (0, 1, 2, 4, 6, 8, 10 
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hrs) and replenished with an amount of medium to maintain 
the receptor phase volume to 20 mL. The samples were 
analyzed spectrophotometrically at 272 nm [12]. 
In order to understand the mechanism and kinetics of drug 
release, the drug release data of the in-vitro drug release was 
analyzed with various kinetic models like zero order, first 
order, Higuchi, Korsmeyer peppas model and correlation co 
efficient values were calculated for the linear curves.  
RESULTS AND DISCUSSION 
Fourier transform infrared spectroscopy (FTIR) 
The IR Spectrum of Tapentadol hydrochloride (Pure drug) 
shoes peaks at 3414.12 cm-1, 1519.96 cm-1, 1383.01 cm-1, 
1163.11 cm-1. The physical mxture on the other hand shows 
peaks at 3423.76 cm-1, 1519.96 cm-1, 1383.01 cm-1, 1163.11 
cm-1. Thus it is concluded that the physical mixture of the 
drug (Tapentadol Hydrochloride) does not show any major 
interactions with the formulation components like lipid 
(Glycerol monostearate) and surfactant (Poloxamer-188). 
This indicates that drug was compatible with the excipients 
which were represented in the figure 1 and figure 2.
 
 
    Figure-1: FTIR Spectra of Tapentadol hydrochloride 
 
Figure-2: FTIR spectra of Optimized Formulation 
Differential Scanning Colorimetry (DSC) 
The best and optimized formulation of Tapentadol 
hydrochloride solid lipid nanaoparticles were evaluated for 
DSC. The pure Tapentadol hydrochloride shows a sharp 
endothermic peak at 212.23˚C and some of the  similar 
changes  occured in endothermic peak were observed at 
similar temperatue in prepared formulation at 209.68˚C. 
Thus it is concluded that,no  interaction between the drug 
and the excipients which were represented in the figure 3 
and figure 4. 
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Figure-3: DSC of Tapentadol hydrochloride 
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Figure-4: DSC of Optimized Formulation 
Scanning Electron Microscopy (SEM) 
The SEM photomicrographs of sample solution (F3 formulation) were obtained and as shown in figure 5. The 
photomicrographs revealed that the surface was smooth and uniform with appearance of spherical shape. 
 
 
Figure-5: SEM images of F3 formulation 
Percent Entrapment Efficiency (%EE) 
Percent drug entrapment efficiency was used to determine 
the amount of drug entrapped into the prepared solid lipid 
nanoparticles.The % Entrapment Efficiency of all the 
formulations ranges between 60.9±0.65 to 8.7±0.36. This 
indicates that increase in drug loading increase the 
percentage of drug entramen efficiency. The %Entrapment 
efficiency values of all the Formulations were given in table 
3 and graph representing the % Entrapment efficiency was 
given in Figure 6. 
 
 
Figure-6: Graph representing the % EE of Formulations 
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Table-3: %EE values of the formulations 
S.N0 Formulation Code %EE±S.D 
1 F1 60.9±0.65 
2 F2 71.6±0.23 
3 F3 88.7±0.36 
4 F4 86.0±0.69 
5 F5 72.9±0.53 
6 F6 75.3±0.80 
7 F7 65.8±0.23 
8 F8 68.3±0.12 
9 F9 85.7±0.63 
10 F10 87.5±0.56 
11 F11 71.0±0.31 
12 F12 74.2±0.11 
 
Zeta Potential  
The zeta potential of the Tapentadol Hcl Solid lipid 
nanoparticles is important to determine the stability and 
uptake mechanism of the particles inside the body. The zeta 
potential values of formulations are shown in table 4 and 
zeta potential values of optimized formulation (F3) are 
shown in figure 7. 
 
Table-4:  Zeta Potential values of the formulations 
S.No. Formulations Code Particle size (nm) Zeta Potential (mV) 
1 F1 252.1 -28.6 
2 F2 280.3 -24.6 
3 F3 101.9 -18.1 
4 F4 89.0 -20.8 
5 F5 132.9 -21.6 
6 F6 159.0 -24.6 
7 F7 307.8 -27.8 
8 F8 348.2 -25.0 
9 F9 198.6 -20.6 
10 F10 172.4 -21.8 
11 F11 125.6 -10.9 
12 F12 121.7 -9.8 
 
 
Figure-7: Graph representing the Zeta potential of Optimized formulation 
 
In vitro drug release studies 
In vitro drug release studies were carried out by using 
Franzz diffusion cell using phosphate buffer (pH 7.4) as a 
dissolution medium which is carried out for about 10 hrs. 
The drug release from all the formulations were found to be 
higher than the pure drug which were given in table 5 and 
table 6 and graphical representations were represented in 
Figures 8,9,10,11The drug release from the optimized 
formulation (F3) was found to be 97.8±0.60 in 10 hours 
following first order release kinetics and Higuchi model.
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Table-5: %Drug release of formulations F1 to F6 
Time (hrs) F1 F2 F3 F4 F5 F6 
0 0 0 0 0 0 0 
1 14.5±0.10 14.6±0.13 15.1±0.20 15.8±0.02 16.1±0.23 17.4±0.43 
2 22.6±0.25 21.2±0.24 25.3±0.13 26.1±0.81 28.0±0.34 24.6±0.65 
3 35.2±0.36 28.7±0.37 31.4±0.32 37.8±1.33 39.3±0.46 36.0±0.87 
4 39.8±0.21 32.5±0.45 37.8±0.83 42.5±1.26 44.3±1.23 47.9±0.76 
5 43.6±0.58 39.7±1.2 42.4±1.40 45.6±0.41 49.19±1.37 54.9±0.45 
6 52.7±0.12 46.5±1.9 49.7±0.90 53.6±0.76 57.8±0.67 65.6±1.34 
7 59.4±0.32 51.9±0.7 58.7±0.15 65.9±1.54 66.8±0.25 71.4±1.98 
8 64.7±0.52 67.8±0.5 75.3±0.12 78.7±0.35 69.1±1.23 84.0±0.57 
9 76.9±0.01 72.8±0.4 83.4±1.40 87.4±0.67 74.9±1.42 95.4±0.34 
10 88.6±0.40 85.0±1.2 97.8±0.60 95.6±1.02 82.7±0.43 97.8±1.24 
 
Table-6: % Drug release of formulations F7 to F12 
Time (hrs) F7 F8 F9 F10 F11 F12 
0 0 0 0 0 0 0 
1 18.2±0.23 16.1±0.20 14.5±0.32 15.9±0.32 17.2±0.45 13.2±0.23 
2 26.2±0.25 21.2±0.36 22.6±0.50 28.3±0.65 25.2±0.58 21.3±0.85 
3 35.2±0.60 32.6±0.51 35.2±0.75 36.9±0.54 36.5±0.14 36.5±0.56 
4 46.3±0.52 44.5±0.66 39.8±0.89 46.5±0.42 43.2±0.23 47.2±0.76 
5 52.6±0.32 59.2±0.52 43.6±0.97 58.9±0.35 58.1±0.54 56.1±0.42 
6 65.2±0.69 66.1±0.32 52.7±1.3 66.4±0.12 65.2±0.36 70.4±0.31 
7 78.5±0.54 75.6±0.21 59.4±1.8 74.2±0.65 75.5±0.87 76.5±0.14 
8 85.6±0.84 86.1±0.32 64.7±2.1 84.5±0.85 78.2±0.56 82.2±0.51 
9 89.5±0.54 89.1±0.11 76.9±0.2 88.9±0.65 81.2±0.32 88.3±0.32 
10 90.2±0.25 91.0±0.28 88.6±1.5 91.6±0.32 90.1±0.25 91.5±0.95 
 
 
Figure-8: % Drug release of F1, F2, F3 Formulations 
 
Figure-9: % Drug release of F4, F5, F6 Formulations 
 
Figure-10: % Drug release of F7, F8, F9 Formulations 
 
Figure-11: % Drug release of F10, F11, F12 Formulations 
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CONCLUSION 
Tapentadol hydrochloride is a drug for the treating of severe 
pain and used as analgesic. Tapentadol Hcl loaded Solid 
Lipid Nanoparticles were prepared with the aim to release 
the drug at a controlled and prolonged rate at the targeted 
site. The Tapentadol hydrochloride Solid Lipid Nanoparticles 
was successfully prepared by using glycerol monostearate 
and Stearic acid as lipids and Poloxamer-188 as a Surfactant 
by Hot Homogenization method. The F1 to F12 Formulations 
were prepared by using different ratios of lipids and 
surfactant. The prepare formulations was evaluated for 
various parameters. 
Tapentadol hydroichloride solid Lipid Nanoparticles 
prepared by using 0.6% of Glycerol monostearate and 0.25 
% of Poloxamer-188 is effective when compared to other 
formulations. SEM study of prepared SLN’s was within the 
range of (1-1000 nm). There is no drug- excipients 
interaction in FTIR and DSC. The % Entrapment Efficiency 
was found as 88.7±0.36.  the Zeta potential was found as -
18.1mV.The % drug release was found as 97.8±0.60  in 10 
hrs following first order release kinetics and Higuchi model. 
Stability studies were done for 3 months and the 
formulation was stable without any physical changes and 
degradation.   
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